Saturday 17 October 2026
Export CELC’s income statement to Excel — free account
Celcuity, Inc.
CELC Healthcare Biotechnology
In the quarter to June 2026, EPS fell 38.5%, free cash flow fell 53.3% and total debt rose 658.7%, each against the same quarter a year earlier.
56.16
4.14
−6.87%
Follow CELC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(122.04%) | (163.80%) | (275.17%) | (1,433.70%) | |
| (43.45%) | (49.75%) | (61.40%) | (44.77%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(37.23%) | (41.95%) | (51.25%) | (32.84%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(3.04) | (3.28) | (3.18) | (3.51) | |
Free Cash Flow |
(144.89) | (153.53) | (172.97) | (192.28) | |
Capital Expenditures |
(0.24) | (0.25) | (0.47) | (0.57) | |
| Other line items | |||||
Cash ROIC |
(16.24%) | (17.77%) | (22.64%) | (12.87%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(11.18) | (10.04) | (9.30) | (9.37) | |
Operating CF/Net income |
0.89 | 0.87 | 0.89 | 0.85 | |
Depreciation/Fixed assets |
6.16 | 6.62 | 6.49 | 7.71 | |
Capex/Depreciation |
(0.09) | (0.08) | (0.12) | (0.12) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.04) | (3.28) | (3.17) | (3.50) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates